Abstract
Introduction/BackgroundPaclitaxel or pegylated liposomal doxorubicin (PLD) in combination with bevacizumab constitutes a standard treatment option in patients with relapsed ovarian cancer (ROC) who are not considered candidate for platinum, but...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
